Guy C. Toner

University of Melbourne — Australia

Medicine · Health Sciences

37h-index5.2kcitations173works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Testicular diseases and treatments(66), Sarcoma Diagnosis and Treatment(34), Cancer Treatment and Pharmacology(27), Neuroblastoma Research and Treatments(23), Neutropenia and Cancer Infections(17)

Publications173 total

The utility of genomics and functional imaging to predict sunitinib pharmacokinetics and pharmacodynamics: The predict SU study
British Journal of Clinical Pharmacology·2026
Pembrolizumab and Denosumab in clear-cell renal-cell carcinoma
SSRN Electronic Journal·2025Open Access
1886P Pembrolizumab and denosumab in clear cell renal cell carcinoma (ccRCC): A phase II trial (KeyPAD, ANZUP1601)
Annals of Oncology·2023· 2 citedOpen Access
The Utility of Genomics and Functional Imaging to Predict Sunitinib Pharmacokinetics and Pharmacodynamics: The Predict Su Study
Research Square (Research Square)·2023Open Access
Patterns of Relapse in Australian Patients With Clinical Stage 1 Testicular Cancer: Utility of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Surveillance Recommendations
JCO Oncology Practice·2023· 7 cited
Two decades of FDG-PET/CT in seminoma: exploring its role in diagnosis, surveillance and follow-up
Cancer Imaging·2022· 10 citedOpen Access
High‐dose chemotherapy for relapsed germ cell tumours: outcomes in low‐volume specialized centres
British Journal of Urology·2022· 8 citedOpen Access
Clinical utility of FDG PET-CT in stage 1 and advanced testicular seminoma.
Journal of Clinical Oncology·2021· 2 cited
P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumors (GCTs).
Journal of Clinical Oncology·2021· 1 cited
Denosumab and pembrolizumab in clear cell renal carcinoma (KEYPAD): A phase II trial (ANZUP1601).
Journal of Clinical Oncology·2021· 2 cited
Exploring the role for FDG-PET/CT in testicular seminoma at diagnosis and during active surveillance across the disease spectrum
Asia-Pacific Journal of Clinical Oncology·2021
Online psychological self-management intervention for testicular cancer survivors (e-TC 2.0): promising acceptability and preliminary efficacy, but limited feasibility
Journal of Psychosocial Oncology Research and Practice·2020· 7 citedOpen Access
P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for adult and pediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs).
Journal of Clinical Oncology·2020
The impact of chemotherapy on cognitive function: a multicentre prospective cohort study in testicular cancer
Supportive Care in Cancer·2019· 24 cited
Pulmonary function testing for the early detection of drug‐induced lung disease: a systematic review in adults treated with drugs associated with pulmonary toxicity
Internal Medicine Journal·2019· 12 cited
OC-0277 Interim safety analysis of RAPPORT trial - SABR with pembrolizumab in oligometastatic RCC
Radiotherapy and Oncology·2019· 1 citedOpen Access
P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for adult and pediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs).
Journal of Clinical Oncology·2019
Protocol for the P3BEP trial (ANZUP 1302): an international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours
BMC Cancer·2018· 7 citedOpen Access
ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up
Annals of Oncology·2018· 319 citedOpen Access
The utility of genomics and functional imaging to predict Sunitinib PK and PD: The Predict SU study.
Journal of Clinical Oncology·2018
page 1 of 9Next →

Frequent Co-authors

Danny Rischin(12), Ian Olver(9), James F. Bishop(8), Peter Grimison(8), Howard Gurney(7), Martin R. Stockler(7), George J. Bosl(5), Michael Millward(5), Nancy L. Geller(4), Ewout W. Steyerberg(4), H.J. Keizer(4), John P. Donohue(4), I. N. Olver(4), Val Gebski(4), Rodney J. Hicks(4), Michael Millward(3), Dirk Th. Sleijfer(3), Jonathan E. Messemer(3), John A. Levi(3), Gerard Powell(3)